PDB ID,Uniprot ID,Paper ,Title,Ligand 3 character Code
2D3U,Q99AU2,https://pubs.acs.org/doi/10.1021/ja512751q,X-ray crystal structure of hepatitis C virus RNA dependent RNA polymerase in complex with non-nucleoside analogue inhibitor,res.ptype 'CCT'
1AJQ,P06875;P06875,https://pubs.acs.org/doi/10.1021/ja512751q,PENICILLIN ACYLASE COMPLEXED WITH THIOPHENEACETIC ACID,res.ptype 'SPA'
1E66,P04058,https://pubs.acs.org/doi/10.1021/ja512751q,STRUCTURE OF ACETYLCHOLINESTERASE COMPLEXED WITH (-)-HUPRINE X AT 2.1A RESOLUTION,res.ptype 'HUX'
1B7H,P06202,https://pubs.acs.org/doi/10.1021/ja512751q,OLIGO-PEPTIDE BINDING PROTEIN COMPLEXED WITH LYSYL-NORLEUCYL-LYSINE,res.ptype 'U1'
1XD1,P04746,https://pubs.acs.org/doi/10.1021/ja512751q,Acarbose Rearrangement Mechanism Implied by the Kinetic and Structural Analysis of Human Pancreatic alpha-Amylase in Complex with Analogues and Their Elongated Counterparts,res.ptype '6SA'
2CEQ,P22498,https://pubs.acs.org/doi/10.1021/ja512751q,Beta-glycosidase from Sulfolobus solfataricus in complex with glucoimidazole,res.ptype 'GIM'
2CER,P22498,https://pubs.acs.org/doi/10.1021/ja512751q,Beta-glycosidase from Sulfolobus solfataricus in complex with phenethyl-substituted glucoimidazole,res.ptype 'PGI'
2QWE,P03472,https://pubs.acs.org/doi/10.1021/ja512751q,THE X-RAY STRUCTURE OF A COMPLEX OF 4-GUANIDINO-NEU5AC2EN AND A DRUG RESISTANT VARIANT R292K OF TERN N9 INFLUENZA VIRUS NEURAMINIDASE,res.ptype 'ZMR'
2CET,Q08638,https://pubs.acs.org/doi/10.1021/ja512751q,Beta-glucosidase from Thermotoga maritima in complex with phenethyl- substituted glucoimidazole,res.ptype 'PGI'
1M0Q,P16932,https://pubs.acs.org/doi/10.1021/ja512751q,Structure of Dialkylglycine Decarboxylase Complexed with S-1-aminoethanephosphonate,res.ptype 'EPC'
2G94,P56817,https://pubs.acs.org/doi/10.1021/ja512751q,Crystal structure of beta-secretase bound to a potent and highly selective inhibitor.,res.ptype 'ZPQ'
1OLS,P12694;P21953,https://pubs.acs.org/doi/10.1021/ja512751q,Roles of His291-alpha and His146-beta' in the reductive acylation reaction catalyzed by human branched-chain alpha-ketoacid dehydrogenase,res.ptype 'TPP'
1TOI,P00509,https://pubs.acs.org/doi/10.1021/ja512751q,Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase,res.ptype 'HCI'
1N2V,P28720,https://pubs.acs.org/doi/10.1021/ja512751q,"Crystal Structure of TGT in complex with 2-Butyl-5,6-dihydro-1H-imidazo[4,5-d]pyridazine-4,7-dione",res.ptype 'BDI'
1S39,P28720,https://pubs.acs.org/doi/10.1021/ja512751q,CRYSTAL STRUCTURE OF TGT IN COMPLEX WITH 2-aminoquinazolin-4(3H)-one,res.ptype 'AQO'
2BAJ,Q16539,https://pubs.acs.org/doi/10.1021/ja512751q,p38alpha bound to pyrazolourea,res.ptype 'PQB'
1NDZ,P56658,https://pubs.acs.org/doi/10.1021/ja512751q,Crystal Structure of Adenosine Deaminase Complexed with FR235999,res.ptype 'FR5'
1XGJ,P00811,https://pubs.acs.org/doi/10.1021/ja512751q,AmpC beta-lactamase in complex with 3-(4-carboxy-2-hydroxy-phenylsulfamoyl)-thiophene-2-carboxylic acid,res.ptype 'XXX'
1RE8,P05132,https://pubs.acs.org/doi/10.1021/ja512751q,Crystal structure of cAMP-dependent protein kinase complexed with balanol analog 2,res.ptype 'BD2'
1FZK,P01901;P01887;P04857,https://pubs.acs.org/doi/10.1021/ja512751q,MHC CLASS I NATURAL MUTANT H-2KBM1 HEAVY CHAIN COMPLEXED WITH BETA-2 MICROGLOBULIN AND SENDAI VIRUS NUCLEOPROTEIN,res.ptype 'NAG'
1ZOE,P28523,https://pubs.acs.org/doi/10.1021/ja512751q,Crystal structure of protein kinase CK2 in complex with TBB-derivatives inhibitors,res.ptype 'K25'
1NNY,P18031,https://pubs.acs.org/doi/10.1021/ja512751q,"Potent, Selective Protein Tyrosine Phosphatase 1B Inhibitor Compound 23 Using a Linked-Fragment Strategy",res.ptype '515'
4ER2,P11838,https://pubs.acs.org/doi/10.1021/ja512751q,The active site of aspartic proteinases,res.ptype 'SO4'
1BXO,P00798,https://pubs.acs.org/doi/10.1021/ja512751q,ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL CYCLO[(2S)-2-[[(1R)-1-(N-(L-N-(3-METHYLBUTANOYL)VALYL-L-ASPARTYL)AMINO)-3-METHYLBUT YL] HYDROXYPHOSPHINYLOXY]-3-(3-AMINOMETHYL) PHENYLPROPANOATE,res.ptype 'FAD'
1NJA,P00469,https://pubs.acs.org/doi/10.1021/ja512751q,"THYMIDYLATE SYNTHASE, MUTATION, N229C WITH 2'-DEOXYCYTIDINE 5'-MONOPHOSPHATE (DCMP)",res.ptype 'DCM'
4TMN,P00800,https://pubs.acs.org/doi/10.1021/ja512751q,SLOW-AND FAST-BINDING INHIBITORS OF THERMOLYSIN DISPLAY DIFFERENT MODES OF BINDING. CRYSTALLOGRAPHIC ANALYSIS OF EXTENDED PHOSPHONAMIDATE TRANSITION-STATE ANALOGUES,res.ptype '0PK'
1FH8,P07986,https://pubs.acs.org/doi/10.1021/ja512751q,CRYSTAL STRUCTURE OF THE XYLANASE CEX WITH XYLOBIOSE-DERIVED ISOFAGOMINE INHIBITOR,res.ptype 'XYP'
1D09,P0A786;P0A7F3,https://pubs.acs.org/doi/10.1021/ja512751q,ASPARTATE TRANSCARBAMOYLASE COMPLEXED WITH N-PHOSPHONACETYL-L-ASPARTATE (PALA),res.ptype 'PAL'
7CPA,P00730,https://pubs.acs.org/doi/10.1021/ja512751q,COMPARISON OF THE STRUCTURES OF THREE CARBOXYPEPTIDASE A-PHOSPHONATE COMPLEXES DETERMINED BY X-RAY CRYSTALLOGRAPHY,res.ptype 'FVF'
1PXO,P24941,https://pubs.acs.org/doi/10.1021/ja512751q,HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine,res.ptype 'RPN'
1SL3,P00734;P28504,https://pubs.acs.org/doi/10.1021/ja512751q,crystal structue of Thrombin in complex with a potent P1 heterocycle-Aryl based inhibitor,res.ptype '170'
1NVQ,O14757,https://pubs.acs.org/doi/10.1021/ja512751q,The Complex Structure Of Checkpoint Kinase Chk1/UCN-01,res.ptype 'UCN'
2AOU,P50135;P50135,https://pubs.acs.org/doi/10.1021/ja512751q,Histamine Methyltransferase Complexed with the Antimalarial Drug Amodiaquine,res.ptype 'CQA'
1PBQ,P35439,https://pubs.acs.org/doi/10.1021/ja512751q,"CRYSTAL STRUCTURE OF THE NR1 LIGAND BINDING CORE IN COMPLEX WITH 5,7-DICHLOROKYNURENIC ACID (DCKA) AT 1.90 ANGSTROMS RESOLUTION",res.ptype 'DK1'
1B8O,P55859,https://pubs.acs.org/doi/10.1021/ja512751q,PURINE NUCLEOSIDE PHOSPHORYLASE,res.ptype 'IMH'
1FTM,P19491,https://pubs.acs.org/doi/10.1021/ja512751q,CRYSTAL STRUCTURE OF THE GLUR2 LIGAND BINDING CORE (S1S2J) IN COMPLEX WITH AMPA AT 1.7 RESOLUTION,res.ptype 'AMQ'
1FCZ,P13631,https://pubs.acs.org/doi/10.1021/ja512751q,ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE PANAGONIST RETINOID BMS181156,res.ptype 'LMU'
1F4G,P0A884,Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field | Journal of the American Chemical Society,CRYSTAL STRUCTURE OF E. COLI THYMIDYLATE SYNTHASE COMPLEXED WITH SP-876,res.ptype 'TP4'
1SQA,P00749,https://pubs.acs.org/doi/10.1021/ja512751q,Substituted 2-Naphthamidine Inhibitors of Urokinase,res.ptype 'UI1'
2AYR,P03372,https://pubs.acs.org/doi/10.1021/ja512751q,A SERM Designed for the Treatment of Uterine Leiomyoma with Unique Tissue Specificity for Uterus and Ovaries in Rats,res.ptype 'L4G'
1IF7,P00918,https://pubs.acs.org/doi/10.1021/ja512751q,Carbonic Anhydrase II Complexed With (R)-N-(3-Indol-1-yl-2-methyl-propyl)-4-sulfamoyl-benzamide,res.ptype 'SBR'
1NFY,P00742;P00742,https://pubs.acs.org/doi/10.1021/ja512751q,CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR200095,res.ptype 'RTR'
1MQ6,P00742;P00742,https://pubs.acs.org/doi/10.1021/ja512751q,"Crystal Structure of 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[[(4,5-dihydro-2-oxazolyl)methylamino]methyl]-2-thiophenecarboxamide Complexed with Human Factor Xa",res.ptype 'XLD'
1HFS,P08254,https://pubs.acs.org/doi/10.1021/ja512751q,"CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN FIBROBLAST STROMELYSIN-1 INHIBITED WITH THE N-CARBOXY-ALKYL INHIBITOR L-764,004",res.ptype 'L04'
2BZ6,P08709;P08709,https://pubs.acs.org/doi/10.1021/ja512751q,Orally available Factor7a inhibitor,res.ptype '346'
2B7D,P08709;P08709;P13726,https://pubs.acs.org/doi/10.1021/ja512751q,"Factor VIIa Inhibitors: Chemical Optimization, Preclinical Pharmacokinetics, Pharmacodynamics, and Efficacy in a Baboon Thrombosis Model",res.ptype 'C1B'
1X1Z,O26232,https://pubs.acs.org/doi/10.1021/ja512751q,Orotidine 5'-monophosphate decarboxylase (odcase) complexed with BMP (produced from 6-cyanoump),res.ptype 'BMP'
1TRD,P04789,https://pubs.acs.org/doi/10.1021/ja512751q,THE INFLUENCE OF CRYSTAL PACKING ON CRYSTALLOGRAPHIC BINDING STUDIES: A NEW CRYSTAL FORM OF TRYPANOSOMAL TIM,res.ptype 'PGH'
1UTP,P00760,https://pubs.acs.org/doi/10.1021/ja512751q,"Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements",res.ptype 'PBN'
1O3F,P00760,https://pubs.acs.org/doi/10.1021/ja512751q,Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors,res.ptype '696'
1Y6Q,P0AF12,https://pubs.acs.org/doi/10.1021/ja512751q,Cyrstal structure of MTA/AdoHcy nucleosidase complexed with MT-DADMe-ImmA,res.ptype 'TDI'
1ELB,P00772,https://pubs.acs.org/doi/10.1021/ja512751q,Analogous inhibitors of elastase do not always bind analogously,res.ptype '0Z4'
1K9S,P0ABP8,https://pubs.acs.org/doi/10.1021/ja512751q,PURINE NUCLEOSIDE PHOSPHORYLASE FROM E. COLI IN COMPLEX WITH FORMYCIN A DERIVATIVE AND PHOSPHATE,res.ptype 'FM2'
3PCJ,P00436;P00437,https://pubs.acs.org/doi/10.1021/ja512751q,"STRUCTURE OF PROTOCATECHUATE 3,4-DIOXYGENASE COMPLEXED WITH 2-HYDROXYISONICOTINIC ACID N-OXIDE",res.ptype 'CLA'
1FLR,1589925;P01865,https://pubs.acs.org/doi/10.1021/ja512751q,4-4-20 FAB FRAGMENT,res.ptype 'FLU'
10GS,P09211,https://pubs.acs.org/doi/10.1021/ja512751q,"HUMAN GLUTATHIONE S-TRANSFERASE P1-1, COMPLEX WITH TER117",res.ptype 'VWW'
3STD,P56221,https://pubs.acs.org/doi/10.1021/ja512751q,SCYTALONE DEHYDRATASE AND CYANOCINNOLINE INHIBITOR,res.ptype 'MQ0'
1ZVX,P22894,https://pubs.acs.org/doi/10.1021/ja512751q,Crystal structure of the complex between MMP-8 and a phosphonate inhibitor (R-enantiomer),res.ptype 'FIN'
2DRC,P0ABQ4,https://pubs.acs.org/doi/10.1021/ja512751q,INVESTIGATION OF THE FUNCTIONAL ROLE OF TRYPTOPHAN-22 IN ESCHERICHIA COLI DIHYDROFOLATE REDUCTASE BY SITE-DIRECTED MUTAGENESIS,res.ptype 'MTX'
2F01,P22629,https://pubs.acs.org/doi/10.1021/ja512751q,Epi-biotin complex with core streptavidin,res.ptype 'BTQ'
1U1B,P61823,https://pubs.acs.org/doi/10.1021/ja512751q,Structure of bovine pancreatic Ribonuclease A in complex with 3'-phosphothymidine (3'-5')-pyrophosphate adenosine 3'-phosphate,res.ptype 'PAX'
2BZZ,P10153,https://pubs.acs.org/doi/10.1021/ja512751q,"Crystal Structures of Eosinophil-derived Neurotoxin in Complex with the Inhibitors 5'-ATP, Ap3A, Ap4A and Ap5A",res.ptype 'AP5'
2G5U,P02766,https://pubs.acs.org/doi/10.1021/ja512751q,"Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4,4'-dihydroxy-3,3',5,5'-tetrachlorobiphenyl",res.ptype 'PCQ'
1JQ9,P59071,https://pubs.acs.org/doi/10.1021/ja512751q,Crystal structure of a complex formed between phospholipase A2 from Daboia russelli pulchella and a designed pentapeptide Phe-Leu-Ser-Tyr-Lys at 1.8 resolution,res.ptype 'ACY'
1IS0,P00524,https://pubs.acs.org/doi/10.1021/ja512751q,Crystal Structure of a Complex of the Src SH2 Domain with Conformationally Constrained Peptide Inhibitor,res.ptype 'XXX'
2I0D,O38731,https://pubs.acs.org/doi/10.1021/ja512751q,Crystal structure of AD-81 complexed with wild type HIV-1 protease,res.ptype 'MUT'
1FKB,P62942,https://pubs.acs.org/doi/10.1021/ja512751q,ATOMIC STRUCTURE OF THE RAPAMYCIN HUMAN IMMUNOPHILIN FKBP-12 COMPLEX,res.ptype 'RAP'
1RNT,P00651,https://pubs.acs.org/doi/10.1021/ja512751q,RESTRAINED LEAST-SQUARES REFINEMENT OF THE CRYSTAL STRUCTURE OF THE RIBONUCLEASE T1(ASTERISK)2(PRIME)-GUANYLIC ACID COMPLEX AT 1.9 ANGSTROMS RESOLUTION,res.ptype '2GP'
1H1Q,P24941;P20248,https://pubs.acs.org/doi/10.1021/ci9000053,Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6094,res.ptype '2A6'
2GMX,P45983;Q9UQF2,https://pubs.acs.org/doi/10.1021/ci9000053,Selective Aminopyridine-Based C-Jun N-terminal Kinase inhibitors with cellular activity,res.ptype '877'
2QBS,P18031,https://pubs.acs.org/doi/10.1021/ci9000054,Crystal structure of ptp1b-inhibitor complex,res.ptype '024'
2ZFF,P00734;P00734;P01050,https://pubs.acs.org/doi/10.1021/ci9000055,Exploring Thrombin S1-pocket,res.ptype '53U'
3FLY,Q16539,https://pubs.acs.org/doi/10.1021/ci9000056,"P38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)-2-isopropylamino-8-methyl-8h-pyrido[2,3-d]pyrimidin-7-one",res.ptype 'FLY'
3FMH,Q16539,https://pubs.acs.org/doi/10.1021/ci9000057,"P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-8-methyl-2-((R)-1-methyl-2-tetrazol-2-yl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one",res.ptype '533'
3FMK,Q16539,https://pubs.acs.org/doi/10.1021/ci9000058,"P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-8-methyl-2-((S)-1-methyl-2-tetrazol-2-yl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one",res.ptype 'FMK'
4DJW,P56817,https://pubs.acs.org/doi/10.1021/ci9000059,Structure of BACE Bound to 2-imino-3-methyl-5-phenyl-5-(3-(pyridin-3-yl)phenyl)imidazolidin-4-one,res.ptype '0KP'
4GIH,P29597,https://pubs.acs.org/doi/10.1021/ci9000060,"Tyk2 (JH1) in complex with 2,6-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE",res.ptype '0X5'
4HW3,Q07820,https://pubs.acs.org/doi/10.1021/ci9000061,Discovery of potent Mcl-1 inhibitors using fragment-based methods and structure-based design,res.ptype '19G'
1S63,P49354;P49356,,"Human protein farnesyltransferase complexed with L-778,123 and FPP",res.ptype 'FPP'
1S64,Q04631;P53610,,"Rat protein geranylgeranyltransferase type-I complexed with L-778,123 and a sulfate anion",res.ptype '778'
1SA4,P49354;P49356,,human protein farnesyltransferase complexed with FPP and R115777,res.ptype 'JAN'
1SA5,Q04631;Q02293,,Rat protein farnesyltransferase complexed with FPP and BMS-214662,res.ptype 'BMV'
2XBV,P00742;P00742,,"Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor",res.ptype 'XBV'
2XBW,P00742;P00742,,"Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor",res.ptype '455'
2XBX,P00742;P00742,,"Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor",res.ptype 'RR8'
2XBY,P00742;P00742,,"Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor",res.ptype '63C'
2XC0,P00742;P00742,,"Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor",res.ptype '8NC'
2XC4,P00742;P00742,,"Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor",res.ptype 'IVK'
2XC5,P00742;P00742,,"Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor",res.ptype 'OYJ'
3HQW,Q9QYJ6,,Discovery of novel inhibitors of PDE10A,res.ptype 'PF4'
3HQY,Q9QYJ6,,Discovery of novel inhibitors of PDE10A,res.ptype 'PF6'
3HQZ,Q9QYJ6,,Discovery of novel inhibitors of PDE10A,res.ptype 'PF8'
3HR1,Q9QYJ6,,Discovery of novel inhibitors of PDE10A,res.ptype 'PF9'
3KRJ,P07333,,cFMS tyrosine kinase in complex with 4-Cyano-1H-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide,res.ptype 'KRJ'
3KRL,P07333,,cFMS Tyrosine kinase in complex with 5-Cyano-furan-2-carboxylic acid [4-(4-methyl-piperazin-1-yl)-2-piperidin-1-yl-phenyl]-amide,res.ptype 'KRL'
3LN0,Q05769,,Structure of compound 5c-S bound at the active site of COX-2,res.ptype '52B'
3LN1,Q05769,,Structure of celecoxib bound at the COX-2 active site,res.ptype 'HEM'
3MNR,P07900,,Crystal Structure of Benzamide SNX-1321 bound to Hsp90,res.ptype 'SD1'
3MQE,Q05769,,Structure of SC-75416 bound at the COX-2 active site,res.ptype '416'
3NTG,Q05769,,Crystal structure of COX-2 with selective compound 23d-(R),res.ptype 'HEM'
3S41,P35557,,Glucokinase in complex with activator and glucose,res.ptype 'S41'
3SFK,Q08210,,Crystal structure of Plasmodium falciparum dihydroorotate dehydrogenase bound with Inhibitor DSM267,res.ptype 'ORO'
3UW4,P98170,,Crystal structure of cIAP1 BIR3 bound to GDC0152,res.ptype '0DQ'
3UW5,P98170,,Crystal structure of the BIR domain of MLIAP bound to GDC0152,res.ptype '0DQ'
3ZZE,P08581,,"Crystal structure of C-MET kinase domain in complex with N'-((3Z)-4- chloro-7-methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2-(4- hydroxyphenyl)propanohydrazide",res.ptype '6XP'
3ZXZ,P08581,,X-ray Structure of PF-04217903 bound to the kinase domain of c-Met,res.ptype 'KRW'
4A1Z,P52732,,Eg5-1,res.ptype 'ADP'
4A28,P52732,,Eg5-2,res.ptype 'ADP'
4AOI,P08581,,"Crystal structure of C-MET kinase domain in complex with 4-(3-((1H- pyrrolo(2,3-b)pyridin-3-yl)methyl)-(1,2,4)triazolo(4,3-b)(1,2,4) triazin-6-yl)benzonitrile",res.ptype '4K0'
4AP7,P08581,,"Crystal structure of C-MET kinase domain in complex with 4-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,3-b)(1,2,4)triazin-3-yl)methyl)phenol",res.ptype 'F47'
4AS7,P52732,,Eg5 complex 1,res.ptype '6LX'
4B05,P56817,,"Preclinical characterization of AZD3839, a novel clinical candidate BACE1 inhibitor for the treatment of Alzheimer Disease",res.ptype '32D'
4B7B,P52732,,Eg5-3,res.ptype 'ADP'
4BXN,P52732,,Eg5(WT) complex,res.ptype '6LX'
4C66,O60885,,Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains,res.ptype 'H4C'
4C67,O60885,,Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains,res.ptype 'L5S'
4CDC,P53634;P53634;P53634,,Human DPP1 in complex with (2S)-2-amino-N-((1S)-1-cyano-2-(4- phenylphenyl)ethyl)butanamide,res.ptype '6AO'
4CDD,P53634;P53634;P53634,,Human DPP1 in complex with (2S)-N-((1S)-1-cyano-2-(4-(4-cyanophenyl) phenyl)ethyl)piperidine-2-carboxamide,res.ptype 'GDI'
4CDE,P53634;P53634;P53634,,Human DPP1 in complex with 4-amino-N-((1S)-1-cyano-2-(4-(4- cyanophenyl)phenyl)ethyl)tetrahydropyran-4-carboxamide,res.ptype 'U6B'
4CDF,P53634;P53634;P53634,,"Human DPP1 in complex with (2S,4S)-N-((1S)-1-cyano-2-(4-(4- cyanophenyl)phenyl)ethyl)-4-hydroxy-piperidine-2-carboxamide",res.ptype 'W2C'
4FLH,P48736,,Crystal structure of human PI3K-gamma in complex with AMG511,res.ptype '14K'
4JH0,P27487,,"Crystal structure of dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2) (DPP-IV-WT) complex with bms-767778 AKA 2-(3-(aminomethyl)-4-(2,4- dichlorophenyl)-2-methyl-5-oxo-5,7-dihydro-6h-pyrrolo[3,4- b]pyridin-6-yl)-n,n-dimethylacetamide",res.ptype '1MD'
4LKO,P27487,,Crystal structure of human DPP-IV in complex with BMS-744891,res.ptype '1WH'
4PHW,Q9Y233,,Crystal Structure of PDE10A with 1H-benzimidazol-2-yl(4-((3-(tetrahydro-2H-pyran-4-yl)-2-pyridinyl)oxy)phenyl)methanone,res.ptype '2W1'
4U01,Q9WMX2;F0UY39,,HCV NS3/4A serine protease in complex with 6570,res.ptype '39W'
5AJR,Q7Z1V1,,"Sterol 14-alpha demethylase (CYP51) from Trypanosoma cruzi in complex with the 1-tetrazole derivative VT-1161 ((R)-2-(2,4-Difluorophenyl)-1, 1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl) pyridin-2-yl)propan-2-ol)",res.ptype 'VT1'
5F4N,O14757,,Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737),res.ptype '5UY'
5HLS,O60885,,Crystal structure of the first bromodomain of human BRD4 bound to CPI-0610,res.ptype '62G'
5HM0,O60885,,Crystal structure of the first bromodomain of human BRD4 bound to benzoisoxazoloazepine 3,res.ptype '62V'
5K7K,P11712,,Design and Optimization of Biaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7: Discovery of Clinical Candidate PF-05089771,res.ptype '6RJ'
5MZC,Q84HF5,,"Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) in complex with 3-(5-chloro-6-ethoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)propanoic acid",res.ptype '8EQ'
5MZI,Q84HF5,,"Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) in complex with 3-(5-chloro-6-cyclopropoxy-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl)propanoic acid",res.ptype 'FYK'
5MZK,Q84HF5,,"Pseudomonas fluorescens kynurenine 3-monooxygenase (KMO) in complex with 3-[5-chloro-6-(cyclobutylmethoxy)-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl]propanoic acid",res.ptype 'OK1'
5OQ4,P48736,,"PQR309 - a Potent, Brain-Penetrant, Orally Bioavailable, pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology",res.ptype 'A3W'
5PGU,P28845,,"CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-[2-(4-fluorophenyl)-2-adamantyl]-1-(3-methoxyazetidin-1-yl)ethanone",res.ptype '8K4'
5PGV,P28845,,"CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 1-(3-HYDROXYAZETIDIN-1-YL)-2-[(2S,5R)-2-(4-FLUOROPHENYL)-5-METHOXYADAMANTAN-2-YL]ETHAN-1-ONE",res.ptype '8K7'
5PGW,P28845,,"CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-[(1R,3S,5R,7S)-2-[4-(4-FLUOROPHENYL)PHENYL]-6-HYDROXYADAMANTAN-2-YL]-1-(3- HYDROXYAZETIDIN-1-YL)ETHAN-1-ONE",res.ptype '8KA'
5PGX,P28845,,"CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-(2-BENZYL-6-HYDROXYADAMANTAN-2-YL)-1-(3-HYDROXYAZETIDIN-1-YL)ETHAN-1-ONE",res.ptype '8KD'
5PGY,P28845,,"CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-[(5R,7S)-6-HYDROXY-2-PHENYLADAMANTAN-2-YL]-1-(3-HYDROXYAZETIDIN-1-YL)ETHAN-1-ONE (BMS-816336)",res.ptype '8KG'
5PGZ,P50172,,"CRYSTAL STRUCTURE OF MURINE 11BETA- HYDROXYSTEROIDDEHYDROGENASE COMPLEXED WITH 2-[(5R,7S)-6-HYDROXY-2-PHENYLADAMANTAN-2-YL]-1-(3-HYDROXYAZETIDIN-1-YL)ETHAN-1-ONE (BMS-816336)",res.ptype '8KG'
5QCK,P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3-phenyl-pyrrolidin-2-yl]carbonylamino]benzoic acid",res.ptype 'BUV'
5QCL,P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid",res.ptype 'BUY'
5QCM,P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[[(1~{S})-2-[(~{E})-3-[3-chloranyl-2-fluoranyl-6-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]phenyl]carbamate",res.ptype 'BVJ'
5QCN,P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-5-[(3~{S})-3-ethoxycarbonylpiperidin-1-yl]carbonyl-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid",res.ptype 'BVM'
5QII,P28845,,"CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-(3-(1-(4-CHLOROPHENYL)CYCLOPROPYL) -[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-8-YL)PROPAN-2-OL",res.ptype 'HJG'
5QIJ,P50172,,"CRYSTAL STRUCTURE OF MURINE 11B- HYDROXYSTEROIDDEHYDROGENASE COMPLEXED WITH 2-(3-(1-(4- CHLOROPHENYL)CYCLOPROPYL)-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-8- YL)PROPAN-2-OL",res.ptype 'HJG'
5QQO,P03951;P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(6R)-6-(3-chlorophenyl)-2-oxo-1,3-oxazinan-3-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate",res.ptype 'NRJ'
5QQP,P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(4S)-4-(3-chlorophenyl)-2-oxopiperidin-1-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate",res.ptype 'NR7'
5QTT,P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-{[5-amino-1-(3-chloro-2-fluorophenyl)-1H-pyrazole-4-carbonyl]amino}-3-methyl-2-oxo-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecin-15-yl]carbamate",res.ptype 'QEY'
5QTV,P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-(trifluoromethyl)-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecin-14-yl]carbamate",res.ptype 'QLS'
5QTW,P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecine-2-carboxylate",res.ptype 'QLM'
5QTX,P03951;P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecine-2-carboxylate",res.ptype 'QLD'
5QTY,P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-15-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecine-2-carboxylate",res.ptype 'QLJ'
5QTU,P03951;P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-{[1-(3-chloro-2-fluorophenyl)-5-methyl-1H-imidazole-4-carbonyl]amino}-3-methyl-2-oxo-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecin-15-yl]carbamate",res.ptype 'QEV'
5TQ3,O60674,,Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin,res.ptype '7GZ'
5TQ4,O60674,,Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin,res.ptype '7GY'
5TQ5,O60674,,Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin,res.ptype '7GX'
5TQ6,O60674,,Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin,res.ptype '7GV'
5TQ7,O60674,,Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin,res.ptype '7GT'
5TQ8,O60674,,Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin,res.ptype '7GS'
5TX5,Q13546,,"Rip1 Kinase ( flag 1-294, C34A, C127A, C233A, C240A) with GSK772",res.ptype '7MJ'
5UIR,Q9NWZ3,,Crystal structure of IRAK4 in complex with compound 11,res.ptype '8BY'
5UIS,Q9NWZ3,,Crystal structure of IRAK4 in complex with compound 12,res.ptype '8C1'
5UIT,Q9NWZ3,,Crystal structure of IRAK4 in complex with compound 14,res.ptype '8CD'
5UIU,Q9NWZ3,,Crystal structure of IRAK4 in complex with compound 30,res.ptype '8CG'
5UIQ,Q9NWZ3,,Crystal structure of IRAK4 in complex with compound 9,res.ptype '8BV'
5VP0,O00408,,"Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders",res.ptype '9GJ'
5VP1,O00408,,"Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders",res.ptype '9GA'
5V8Q,P10275,,Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs): Part III,res.ptype '97A'
5WHR,P14902,,Discovery of a novel and selective IDO-1 inhibitor PF-06840003 and its characterization as a potential clinical candidate.,res.ptype 'AOJ'
6BBU,P23458,,Crystal Structure of JAK1 in complex with compound 25,res.ptype 'D7D'
6BBV,O60674,,Crystal Structure of JAK2 in complex with compound 25,res.ptype 'D7D'
6B0Z,O75874,,IDH1 R132H mutant in complex with IDH305,res.ptype 'FLC'
6C0S,P03951,,Factor XIA in complex with the inhibitor methyl (4-{6-[(1S)-2-[(3R)-1-acetylpiperidin-3-yl]-1-({(2E)-3-[5-chloro-2- (1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)ethyl]-3-chloropyridazin-4-yl}phenyl) carbamate,res.ptype 'EEJ'
6E0B,Q08210,,Plasmodium falciparum dihydroorotate dehydrogenase C276F mutant bound with triazolopyrimidine-based inhibitor DSM1,res.ptype 'JZ8'
6E3Z,P56817,,Structure of Bace-1 in complex with Ligand 8,res.ptype 'HRV'
6ENQ,P37231,,Structure of human PPAR gamma LBD in complex with Lanifibranor (IVA337),res.ptype 'BJB'
6H3K,P33981,,"Introduction of a methyl group curbs metabolism of pyrido[3,4-d]pyrimidine MPS1 inhibitors and enables the discovery of the Phase 1 clinical candidate BOS172722.",res.ptype '7PE'
6H6Q,P98170,,Fragment Derived XIAP inhibitor,res.ptype 'FUK'
6H6R,P98170,,Fragment Derived XIAP inhibitor,res.ptype 'FUE'
6HKX,P52732,,Eg5-inhibitor complex,res.ptype 'GCE'
6HKY,P52732,,Eg5-inhibitor complex,res.ptype 'GCE'
6IWI,O76074,,Crystal structure of PDE5A in complex with a novel inhibitor,res.ptype 'B0C'
6JZ0,P00533,,Crystal structure of EGFR kinase domain in complex with compound 78,res.ptype 'CKO'
6O3I,P14902,,Crystal Structure of Human IDO1 bound to navoximod (NLG-919),res.ptype 'LKP'
6RLN,Q13546,,Crystal structure of RIP1 kinase in complex with GSK3145095,res.ptype 'K8K'
6RN8,O43353,,"RIP2 Kinase Catalytic Domain complex with 2(4[(1,3benzothiazol5yl)amino]6(2methylpropane2sulfonyl)quinazolin7yl)oxy)ethyl phosphate",res.ptype 'K9T'
6RNA,O43353,,"RIP2 Kinase Catalytic Domain complex with 2({4[(1,3benzothiazol5yl)amino]6(2methylpropane2sulfonyl)quinazolin7yl}oxy)ethan1ol",res.ptype 'KA2'
6TCZ,Q9UAB4;A0A3Q8IB07;A0A504Y5E1;A0A504XWY9;A0A3Q8IC41;A0A504XQ80;A0A3S5H7H2;A0A504X6A3;A0A3Q8IVH0;A0A3S7X127;A0A504XH29;A0A3Q8IIY4;A0A3S7WPD8;A0A3Q8IIL6,,Leishmania tarentolae proteasome 20S subunit complexed with LXE408,res.ptype 'N2E'
6TD5,Q9UAB4;A0A3Q8IB07;A0A504Y5E1;A0A504XWY9;A0A3Q8IC41;A0A504XQ80;A0A3S5H7H2;A0A504X6A3;A0A3Q8IVH0;A0A3S7X127;A0A504XH29;A0A3Q8IIY4;A0A3S7WPD8;A0A3Q8IIL6,,Leishmania tarentolae proteasome 20S subunit complexed with LXE408 and bortezomib,res.ptype 'BO2'
6USX,P01116,,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer",res.ptype 'M1R'
6USZ,P01116,,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer",res.ptype 'QH4'
6UT0,P01116,,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer",res.ptype 'M1X'
6W35,K7CID1,,A new Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry,res.ptype 'SKV'
6W50,P03951,,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((10R,14S)- 14-(4-(3-CHLORO-2,6-DIFLUOROPHENYL)-6-OXO-3,6-DIHYDRO- 1(2H)-PYRIDINYL)-10-METHYL-9-OXO-8,16- DIAZATRICYCLO[13.3.1.0~2,7~]NONADECA-1(19),2,4,6,15,17- HEXAEN-5-YL)CARBAMATE",res.ptype 'SWP'
6ZGC,Q04771,,Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound Saracatinib (AZD0530),res.ptype 'H8H'
7D9O,P22303,,Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with Compound 2,res.ptype 'H0L'
7D9P,P22303,,Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with Compound 12,res.ptype 'H0R'
7D9Q,P22303,,Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with Compound 7,res.ptype 'H1R'
7E9B,Q15116,,"Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy",res.ptype 'UNK'
7MBO,P03951,,"FACTOR XIA (PICHIA PASTORIS; C500S [C122S]) IN COMPLEX WITH THE INHIBITOR Milvexian (BMS-986177), IUPAC NAME:(6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6- oxopyrimidin-1(6H)-yl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-15,11- (metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one",res.ptype 'YXG'
7M7V,I6X8D2,,Crystal Structure of Mtb Pks13 Thioesterase domain in complex with Compound 6,res.ptype 'Z3J'
7N4N,Q9Y5Z0,,BACE-2 in complex with ligand 36,res.ptype '0BK'
7N5O,Q06187,,Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor,res.ptype 'PGO'
7N5R,Q06187,,Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor,res.ptype '0UW'
7N5X,Q06187,,Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor,res.ptype 'PGO'
7N5Y,Q06187,,"Fragment-Based Drug Design of a Novel, Covalent Bruton's Tyrosine Kinase Inhibitor",res.ptype '0CI'
7N66,P56817,,BACE-1 in complex with ligand 12,res.ptype '0EW'
7N91,P23443,,P70 S6K1 IN COMPLEX WITH MSC2317067A-1,res.ptype '1RJ'
7N93,P23443,,P70 S6K1 IN COMPLEX WITH MSC2363318A-1,res.ptype '1SK'
7NQQ,P28482,,"Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2",res.ptype 'UMN'
7NQW,P28482,,"Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2",res.ptype 'UNW'
7NR3,P28482,,"Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2",res.ptype 'UO5'
7NR5,P28482,,"Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2",res.ptype 'UOH'
7NR8,P28482,,"Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2",res.ptype 'UOE'
7NR9,P28482,,"Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2",res.ptype 'UOW'
7QJG,O75530;Q15910,,EED in complex with PRC2 allosteric inhibitor compound 6,res.ptype 'EKR'
7QJU,O75530;Q15910,,EED in complex with PRC2 allosteric inhibitor compound 7,res.ptype 'EKF'
7QK4,O75530;Q15910,,EED in complex with PRC2 allosteric inhibitor compound 22 (MAK683),res.ptype 'EJR'
7QPF,Q9Y233,,"Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate",res.ptype 'EFJ'
7QPM,Q9Y233,,"Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate",res.ptype 'EEI'
7QPQ,Q9Y233,,"Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate",res.ptype 'EIH'
7QPV,Q9Y233,,"Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate",res.ptype 'EHI'
7QQ4,Q9Y233,,"Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate",res.ptype 'EIK'
7RFR,P0DTD1,,Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor,res.ptype '4W8'
7RFS,P0DTD1,,Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor,res.ptype '4WI'
7RFU,P0DTD1,,Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor,res.ptype '4YG'
7RFW,P0DTD1,,Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor,res.ptype '4WI'
7T78,P35557,,"CRYSTAL STRUCTURE OF GLUCOKINASE (HEXOKINASE 4) COMPLEXED WITH LIGAND DIETHYL ({2-[3-(4-METHANESULFONYLPHENO XY)-5-{[(2S)-1-METHOXYPROPAN-2-YL]OXY}BENZAMIDO]-1,3-THIAZ OL-4-YL}METHYL)PHOSPHONATE",res.ptype 'G2T'
7T79,P35557,,CRYSTAL STRUCTURE OF GLUCOKINASE (HEXOKINASE 4) COMPLEXED WITH LIGAND AKA DIETHYL {[3-(3-{[5-(AZETIDINE-1-CARBON YL)PYRAZIN-2-YL]OXY}-5-(PROPAN-2-YLOXY)BENZAMIDO)-1H- PYRAZOL-1-YL]METHYL}PHOSPHONATE,res.ptype 'G1S'
7VTH,P0DTD1,,The crystal structure of SARS-CoV-2 3CL protease in complex with compound 1,res.ptype '7XB'
7VU6,P0DTD1,,The crystal structure of SARS-CoV-2 3CL protease in complex with compound 3,res.ptype '7YY'
8C9W,P0ABE7,,Crystal structure of the adenosine A2A receptor (construct A2A-PSB2-bRIL) complexed with Etrumadenant at the orthosteric pocket,res.ptype 'U30'
8CIC,P0ABE7,,Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with clinical candidate Etrumadenant,res.ptype 'U30'
8GBU,P03147,,Hepatitis B capsid Y132A mutant with compound AB-506,res.ptype 'YWE'
8HTR,P10415,,Crystal structure of Bcl2 in complex with S-9c,res.ptype 'MWH'
8HTS,P10415,,Crystal structure of Bcl2 in complex with S-10r,res.ptype 'N2L'
8V4U,P0DTD1,,Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor,res.ptype 'YDL'
9BFB,P15056,,Crystal structure of BRAF kinase domain with PF-07284890,
9C0P,I6X8D2,,M. tuberculosis PKS13 acyltransferase (AT) domain in complex with SuFEx inhibitor CEC215,
9C1V,I6X8D2,,M. tuberculosis PKS13 acyltransferase (AT) domain in complex with SuFEx inhibitor CMX410,
9C2R,I6X8D2,,M. tuberculosis PKS13 acyltransferase (AT) domain sulfate free apo form,res.ptype '1PE'